Verastem's Series B - II Round

Verastem raised a round of funding on November 10, 2011.

Verastem is a biopharmaceutical company focused on discovering and developing drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metasta…

Articles about Verastem's Series B - II Round: